A daunting task: manipulating leukocyte function with RNAi

RNA interference (RNAi) has advanced into clinical trials. In spite of the progress made in systemic RNAi delivery to the liver and solid tumors, delivery of RNAi to leukocytes remains challenging and less advanced. Manipulating leukocyte function with RNAi holds great promise for streamlining the drug discovery process by facilitating in vivo drug target validation and for facilitating the development of RNAi‐based therapy platforms for leukocyte‐implicated diseases, such as blood cancer, inflammation, and leukocyte‐tropic viral infections. In this review, progress in delivery strategies of RNAi payloads to leukocytes, which are notoriously difficult cells to transduce with RNAi, is discussed with special emphasis on the challenges and potential opportunities for manipulating leukocyte function with RNAi.

[1]  D. Peer,et al.  Antibody-mediated delivery of siRNAs for anti-HIV therapy. , 2011, Methods in molecular biology.

[2]  I. Maclachlan.  siRNAs with guts , 2008, Nature Biotechnology.

[3]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Nathan F. Bouxsein,et al.  Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery. , 2011, Biochimica et biophysica acta.

[5]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[6]  M. Shimaoka,et al.  Rolling Adhesion through an Extended Conformation of Integrin αLβ2 and Relation to α I and β I-like Domain Interaction , 2004 .

[7]  Sven Frokjaer,et al.  Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. , 2004, Vaccine.

[8]  Landon R. Whitby,et al.  Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification , 2006, Nucleic acids research.

[9]  M. Shimaoka,et al.  Conformational regulation of integrin structure and function. , 2002, Annual review of biophysics and biomolecular structure.

[10]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[12]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[13]  P. Andersen,et al.  Cationic liposomes as vaccine adjuvants , 2007, Expert review of vaccines.

[14]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[15]  P. Sicinski,et al.  Targeting Cyclins and Cyclin-Dependent Kinases in Cancer: Lessons from Mice, Hopes for Therapeutic Applications in Humans , 2006, Cell cycle.

[16]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[17]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[18]  D. Weissman,et al.  Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 31 , 2004, The Journal of Immunology.

[19]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[20]  D. Peer,et al.  Grand challenges in modulating the immune response with RNAi nanomedicines. , 2011, Nanomedicine.

[21]  D. Peer,et al.  RNAi-based nanomedicines for targeted personalized therapy. , 2012, Advanced drug delivery reviews.

[22]  M. Behlke.  Progress towards in Vivo Use of siRNAs , 2006, Molecular Therapy.

[23]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[24]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[25]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[26]  G. Golomb,et al.  Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth. , 2012, Advances in experimental medicine and biology.

[27]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[28]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[29]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[30]  D. Peer.  Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. , 2012, Advanced drug delivery reviews.

[31]  D. Peer.  Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[32]  M. King,et al.  An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation , 2009, Gene Therapy.

[33]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[34]  N. Jing,et al.  Targeting Stat3 in cancer therapy. , 2005, Anti-cancer drugs.

[35]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[36]  P. Campochiaro,et al.  Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 , 2006, Gene Therapy.

[37]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[38]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[39]  D. Peer,et al.  Polysaccharides as building blocks for nanotherapeutics. , 2012, Chemical Society reviews.

[40]  D. Peer,et al.  Integrin-targeted nanoparticles for siRNA delivery. , 2011, Methods in molecular biology.

[41]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[42]  M. Sioud.  Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005, Journal of molecular biology.

[43]  J. Lieberman,et al.  Special delivery: targeted therapy with small RNAs , 2011, Gene Therapy.

[44]  A. Sood,et al.  Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.

[45]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[46]  Dan Peer,et al.  AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes , 2006, Proceedings of the National Academy of Sciences.

[47]  M. Imoto,et al.  Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression , 2007, Cancer science.

[48]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[49]  D. Greiner,et al.  Targeted Delivery of Small Interfering RNA to Human Dendritic Cells To Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production , 2009, Journal of Virology.

[50]  R. Eckert,et al.  In Vitro Internalization, Intracellular Transport, and Clearance of an Anti-CD11a Antibody (Raptiva) by Human T-Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[51]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[52]  M. Amarzguioui,et al.  Approaches for chemically synthesized siRNA and vector‐mediated RNAi , 2005, FEBS letters.

[53]  T. Honda,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D 1 as an Anti-Inflammatory Target , 2022 .

[54]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[55]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[57]  J. Kjems,et al.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity , 2009, Nucleic acids research.

[58]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[59]  V. Hornung,et al.  siRNA and isRNA: two edges of one sword. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[61]  J. Leor,et al.  Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair , 2011, Proceedings of the National Academy of Sciences.

[62]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[63]  H. Paulson,et al.  Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia , 2005, The Journal of Neuroscience.

[64]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[65]  G. Rettig,et al.  Progress Toward In Vivo Use of siRNAs-II , 2006, Molecular Therapy.

[66]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[67]  P. Sicinski,et al.  Cell Cycle Progression without Cyclin D-CDK4 and Cyclin D-CDK6 Complexes , 2005, Cell cycle.

[68]  T. Ishida,et al.  Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[69]  Junichi Takagi,et al.  Structures of the αL I Domain and Its Complex with ICAM-1 Reveal a Shape-Shifting Pathway for Integrin Regulation , 2003, Cell.

[70]  Andrew D. Miller,et al.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.

[71]  S. Agrawal,et al.  Antisense and siRNA as agonists of Toll-like receptors , 2004, Nature Biotechnology.

[72]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[73]  Yang Shi,et al.  RNA Interference Reveals a Requirement for Myocyte Enhancer Factor 2A in Activity-dependent Neuronal Survival* , 2002, The Journal of Biological Chemistry.

[74]  A. Harel-Bellan,et al.  SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. , 2003, Cancer research.

[75]  Jun Li,et al.  Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer* , 2010, The Journal of Biological Chemistry.

[76]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[77]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[79]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[81]  J. Lieberman,et al.  An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection , 2006, Nature.

[82]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[83]  V. Torchilin,et al.  Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Priti Kumar,et al.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[86]  R. Pardi,et al.  Dynamic Partitioning into Lipid Rafts Controls the Endo-Exocytic Cycle of the αL/β2 Integrin, LFA-1, during Leukocyte Chemotaxis , 2005 .

[87]  Y. Yuzawa,et al.  Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[89]  Michael H. Shuman,et al.  Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach , 2011, Nanotechnology.

[90]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[91]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[92]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[93]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[94]  Leaf Huang,et al.  Immunostimulation of dendritic cells by cationic liposomes , 2006, Molecular membrane biology.

[95]  J. Ruysschaert,et al.  Cationic liposomal lipids: from gene carriers to cell signaling. , 2008, Progress in lipid research.

[96]  D. Peer,et al.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.

[97]  A. Eguchi,et al.  Efficient siRNA Delivery into Primary Cells by Peptide Transduction-dsRNA Binding Domain (PTD-DRBD) Fusion Protein , 2009, Nature Biotechnology.

[98]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[99]  Y. Tsutsumi,et al.  Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. , 1997, Biochemical and biophysical research communications.

[100]  F. Szoka.  The Art of Assembly , 2008, Science.

[101]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[102]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[103]  D. Peer,et al.  Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. , 2011, Biomaterials.

[104]  Marion Jurk,et al.  Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 , 2008, The Journal of Immunology.

[105]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[106]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[107]  Dan Peer,et al.  Altering the immune response with lipid-based nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[108]  J. Lieberman,et al.  The silent treatment: siRNAs as small molecule drugs , 2006, Gene Therapy.

[109]  Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. , 2013, Cancer letters.

[110]  R. Pardi,et al.  Dynamic partitioning into lipid rafts controls the endo-exocytic cycle of the alphaL/beta2 integrin, LFA-1, during leukocyte chemotaxis. , 2005, Molecular biology of the cell.

[111]  B. Williams,et al.  RNA interference in biology and disease. , 2005, Blood.

[112]  J. Lieberman,et al.  THE SILENT REVOLUTION : RNA Interference as Basic Biology , Research Tool , and Therapeutic , 2010 .

[113]  O. Keppler,et al.  Efficient nonviral gene delivery into primary lymphocytes from rats and mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[114]  A. Judge,et al.  2'-O-methyl-modified RNAs act as TLR7 antagonists. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[115]  D. Peer,et al.  Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[116]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[117]  Ashley M. Jacobi,et al.  RNA Inhibition Highlights Cyclin D1 as a Potential Therapeutic Target for Mantle Cell Lymphoma , 2012, PloS one.

[118]  M. Shimaoka,et al.  Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. , 2004, Immunity.

[119]  A. Gewirtz.  On future's doorstep: RNA interference and the pharmacopeia of tomorrow. , 2007, The Journal of clinical investigation.

[120]  J. Lieberman,et al.  Knocking down Disease with siRNAs , 2006, Cell.

[121]  T. Ishida,et al.  Accelerated clearance of a second injection of PEGylated liposomes in mice. , 2003, International journal of pharmaceutics.

[122]  Dan Peer,et al.  Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. , 2003, Biochimica et biophysica acta.

[123]  D. Stacey.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. , 2003, Current opinion in cell biology.

[124]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[125]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[126]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[127]  A. Judge,et al.  siRNA and innate immunity. , 2009, Oligonucleotides.

[128]  Haibin Xia,et al.  Allele-specific silencing of dominant disease genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.